mercredi 18 mai 2016

Onco Actu du 18 mai 2016

1.1 Biologie - Gènes

The Power Of Genes, And The Line Between Biology And Destiny [NPR]

2. Etiologie

J&J to stand behind talc's safety at upcoming trials: lawyer [Reuters]

2.3 Etiologie - OGM

Genetically Engineered Crops: Experiences and Prospects [The National Academies Press]

Once again, U.S. expert panel says genetically engineered crops are safe to eat [Science]

2.6 Etiologie - Environnement

UN/WHO panel in conflict of interest row over glyphosate cancer risk [The Guardian]

3.1.1 Tabac - e-cigs

10 common questions about e-cigarettes answered [Cancer Research UK]

3.6 Prévention - Activité physique

Why "exercise lowers cancer risk" headlines mislead readers [HealthNewsReview]

4.12 Biopsies liquides

Foundation Med Gets U.S. Patent For Cancer Analysis [Xconomy]

5. Traitements

Promise of nearly a year of life on targeted drug not reality for all liver cancer patients [UNC Lineberger Comprehensive Cancer Center]

5.10 Traitements - Essais

MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer [Novartis]

Want to really speed up cancer research? Start sharing more data [STAT]

Open medicine [Nature News & Comment]

5.2 Pharma

AstraZeneca's Lynparza fails in gastric cancer combination test [Reuters]

Pascal Soriot's big experiment: reinventing AstraZeneca [Reuters]

5.2.1 Pharma - Partenariats

Celgene pays $200M to start ambitious Agios immuno-oncology pact [FierceBiotech]

Agios, Celgene Jump into Immuno-Oncology in Revamped Alliance [Xconomy]

Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights from 2010 Agreement [Celgene]

Celgene, Agios Expand, Amend Cancer Drug Partnership [The Street]

5.2.3 Pharma - économie

Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis [Novartis]

Novartis pharma head leaves as drug maker splits operations [STAT]

Novartis Pharmaceuticals Head to Depart Amid Restructuring [Wall Street Journal]

Novartis splits drugs business into two, pharma chief to leave [Reuters]

5.3 Traitements - FDA, EMA,...

Progress in science, medicine and health [EMA]

5.3.4 Traitements - AMM (FDA, EMA)

Nivolumab (Opdivo) for Hodgkin Lymphoma [FDA]

Opdivo® (nivolumab) Granted First Approval of a PD-1 Inhibitor in Hematology for the Treatment of Classical Hodgkin Lymphoma Patients Who Have Relapsed or Progressed After Auto-HSCT and Post-transplantation Brentuximab Vedotin by the FDA1 [BMS]

6.1 Observation

HIV-Infected Patients More Likely to Lack Cancer Treatment [ACS]

HIV-infected patients less likely to get cancer treatment [Reuters]

6.10 Politiques

Scientists fight Obama plan to require patient consent to use blood, biopsies in research [STAT]

6.7 DMP, Big Data & applis

EHR Data in Clinical Trials: New FDA Draft Guidance [RAPS]